A Study of RAY1225 in Participants With Obesity

Recruiting now · Phase 2 · Has a placebo group

Conditions studied: Obesity

In brief

The main purpose of this study is to learn more about the Tolerability of RAY1225 in participants with Obesity. The study will also explore the efficacy of RAY1225. The study will last about six months for each participant.

Key facts

Study ID

NCT06254261

Run by

Guangdong Raynovent Biotech Co., Ltd

People needed

270

Starts

2024-02-21

Expected to finish

2025-12-20

Last updated by the study team

2025-03-19

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Have a body mass index (BMI) of ≥28 kilogram per square meter (kg/m²) or ≥24 kg/m² and previously diagnosed with at least one of the following weight related comorbidities: hypertension, dyslipidemia, obstructive sleep apnea, fatty liver disease,or HbA1c ≥5.7% and < 6.5%;
• Participants (including partners) must use reliable methods of contraception during the study and until 6 months following the last dose of investigational product.

You may not qualify if…

• Obesity induced by other endocrinologic disorders or monogenetic or syndromic forms of obesity
• with a history of diabetes or hypoglycemia;
• Have a family or personal history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia (MEN) Syndrome type 2 or with thyroid nodules of unknown etiology found at screening and considered clinically significant by the investigator.
• Have a prior or planned surgical treatment for obesity (excluding liposuction or abdominoplasty if performed >1 year prior to screening)
• allergic constitution;
• not suitable for subcutaneous injection.

Where it is running

• Peking University People's Hospital — Beijingcun, Hebei, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.